Let’s hope this isn’t hype.
1. Press release only; details to be forthcoming
2. All of these studies have the major major confounding factor of the participants being mostly fatties (80-85% of type 2s). SO…You take bad lifestyle people and put them on *any* regimen, and you will probably get “results.”
“The study was designed to assess the effect of Jardiance (empagliflozin) (10mg or 25mg once daily) added to standard of care compared with placebo added to standard of care on CV events in adults with T2D at high risk of CV events and with less than optimised blood glucose control. The study was designed to first test for non-inferiority and then for superiority.”
Of course, those in the study were already sick, and that is the problem with around 100% of all studies done on type 2. What does “high risk of CV events” mean in a practical and quantitative sense?
3. Study compared Jardiance to a placebo. Big deal? How about comparing it to other drugs?
4. And BTW, what if the “standard of care” is making them worse?
5. I will withhold final judgment until the details appear, but this seems like just more crapola. And why no mention of the FDA warning?
Fill in your details below or click an icon to log in:
You are commenting using your WordPress.com account. ( Log Out / Change )
You are commenting using your Twitter account. ( Log Out / Change )
You are commenting using your Facebook account. ( Log Out / Change )
You are commenting using your Google+ account. ( Log Out / Change )
Connecting to %s
Notify me of new comments via email.
Notify me of new posts via email.
Enter your email address to follow this blog and receive notifications of new posts by email.